Interpretation

What the laboratory says this test is for

Peroxisomes play a vital role in several metabolic pathways, including the synthesis of plasmalogens and bile acids. They are also involved in the catabolism of Very Long Chain Fatty Acids (VLCFAs), phytanic acid, and pristanic acid. Defects in these pathways usually result in the accumulation in tissues and body fluids of one or more metabolites derived from the blocked metabolic steps. Specific accumulations are used for the differential biochemical diagnosis of numerous peroxisomal disorders. These disorders include (A) Zellweger spectrum disorders of peroxisomal biogenesis, (B) X-linked adrenoleukodystrophy (X-ALD) and its adult form X-linked adrenomyeloneuropathy (X-AMN), (C) Refsum disease (Phytanoyl-CoA hydroxylase Deficiency), and (D) 2-methylacyl-CoA racemase deficiency.

What the laboratory says this test is for

Essential Fatty Acids (C12-C22), to be used for basic nutritional assessment, identifying fatty acid deficiency, and monitoring patients with fatty acid deficiency who are being treated with a special diet and/or fatty acid supplements.

What the laboratory says this test is for

Comprehensive Fatty Acids (C8-C26), to evaluate patients for certain mitochondrial fatty acid oxidation defects, peroxisomal defects, and/or a full nutritional assessment. It can also be used to monitor patients receiving a special diet and/or fatty acid supplementation.

What the laboratory says this test is for

This panel consists of the three tests recommended by the Centers for Disease Control and Prevention for screening for hepatitis B infection: 1) hepatitis B surface antigen (HBsAg); 2) antibody to hepatitis B surface antigen (anti-HBs); 3) total antibody to hepatitis B core antigen (anti-HBc). Low positive HBsAg samples will be confirmed by a HBsAg neutralization test. Reactive total anti-HBc samples will reflex to an anti-HBc IgM test.This panel can be ordered for universal HBV screening in all adults, including pregnant persons and patients who are at increased risk of acquiring HBV. Current guidelines recommend that asymptomatic adults be screened at least once for HBV. Periodic, repeat testing using this panel can be performed for individuals with appropriate risk factors.ReferenceConners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep. 023;72:1-25.

What the laboratory says this test is for

Mitochondrial Fatty Acids (C8-C18), to be used to evaluate patients for certain mitochondrial fatty acid oxidation defects as well as for monitoring of dietary therapy.